{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:56:16Z","timestamp":1794311776775,"version":"4.9.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA169702"],"award-info":[{"award-number":["R01 CA169702"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA197296"],"award-info":[{"award-number":["R01 CA197296"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA247886"],"award-info":[{"award-number":["P01 CA247886"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA062924"],"award-info":[{"award-number":["P50 CA062924"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A neoadjuvant immunotherapy platform clinical trial allows for rapid evaluation of treatment-related changes in tumors and identifying targets to optimize treatment responses. We enrolled patients with resectable pancreatic adenocarcinoma into such a platform trial (NCT02451982) to receive pancreatic cancer GVAX vaccine with low-dose cyclophosphamide alone (Arm A;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200916), with anti-PD-1 antibody nivolumab (Arm B;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200914), and with both nivolumab and anti-CD137 agonist antibody urelumab (Arm C;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910), respectively. The primary endpoint for Arms A\/B - treatment-related change in IL17A expression in vaccine-induced lymphoid aggregates - was previously published. Here, we report the primary endpoint for Arms B\/C: treatment-related change in intratumoral CD8+ CD137+ cells and the secondary outcomes including safety, disease-free and overall survivals for all Arms. Treatment with GVAX+nivolumab+urelumab meets the primary endpoint by significantly increasing intratumoral CD8+ CD137+ cells (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003) compared to GVAX+Nivolumab. All treatments are well-tolerated. Median disease-free and overall survivals, respectively, are 13.90\/14.98\/33.51 and 23.59\/27.01\/35.55 months for Arms A\/B\/C. GVAX+nivolumab+urelumab demonstrates numerically-improved disease-free survival (HR\u2009=\u20090.55,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.242; HR\u2009=\u20090.51,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.173) and overall survival (HR\u2009=\u20090.59,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.377; HR\u2009=\u20090.53,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.279) compared to GVAX and GVAX+nivolumab, respectively, although not statistically significant due to small sample size. Therefore, neoadjuvant and adjuvant GVAX with PD-1 blockade and CD137 agonist antibody therapy is safe, increases intratumoral activated, cytotoxic T cells, and demonstrates a potentially promising efficacy signal in resectable pancreatic adenocarcinoma that warrants further study.\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-39196-9","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T08:02:57Z","timestamp":1687248177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Thatcher","family":"Heumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Judkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hoare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Celiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7871-3359","authenticated-orcid":false,"given":"Qingfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McPhaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Purtell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Laheru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"De Jesus-Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2110-7697","authenticated-orcid":false,"given":"Dung T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2363-9072","authenticated-orcid":false,"given":"Robert","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-017X","authenticated-orcid":false,"given":"Kevin","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-6549","authenticated-orcid":false,"given":"Elizabeth","family":"Jaffee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-6940","authenticated-orcid":false,"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-2541","authenticated-orcid":false,"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"39196_CR1","doi-asserted-by":"crossref","unstructured":"Sohal DPS, et al. Metastatic pancreatic cancer: ASCO guideline update. J. Clin. Oncol. 38, JCO2001364 (2020).","DOI":"10.1200\/JCO.20.01364"},{"key":"39196_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"39196_CR3","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","volume":"24","author":"ZI Hu","year":"2018","unstructured":"Hu, Z. I. et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin. Cancer Res. 24, 1326\u20131336 (2018).","journal-title":"Clin. Cancer Res."},{"key":"39196_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JCO.2001.19.1.145","volume":"19","author":"EM Jaffee","year":"2001","unstructured":"Jaffee, E. M. et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145\u2013156 (2001).","journal-title":"J. Clin. Oncol."},{"key":"39196_CR5","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-07-0371","volume":"14","author":"D Laheru","year":"2008","unstructured":"Laheru, D. et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin. Cancer Res. 14, 1455\u20131463 (2008).","journal-title":"Clin. Cancer Res."},{"key":"39196_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","volume":"36","author":"DT Le","year":"2013","unstructured":"Le, D. T. et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36, 382\u2013389 (2013).","journal-title":"J. Immunother."},{"key":"39196_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","volume":"2","author":"ER Lutz","year":"2014","unstructured":"Lutz, E. R. et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol. Res. 2, 616\u2013631 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"39196_CR8","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-20-2974","volume":"27","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. Vaccine-induced intratumoral lymphoid aggregates correlate with survival following treatment with a neoadjuvant and adjuvant vaccine in patients with resectable pancreatic adenocarcinoma. Clin. Cancer Res. 27, 1278\u20131286 (2021).","journal-title":"Clin. Cancer Res."},{"key":"39196_CR9","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ccell.2022.10.001","volume":"40","author":"K Li","year":"2022","unstructured":"Li, K. et al. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell. 40, 1374\u20131391.e7 (2022).","journal-title":"Cancer Cell."},{"key":"39196_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.celrep.2017.03.037","volume":"19","author":"T Tsujikawa","year":"2017","unstructured":"Tsujikawa, T. et al. Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. Cell Rep. 19, 203\u2013217 (2017).","journal-title":"Cell Rep."},{"key":"39196_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/eji.201445388","volume":"46","author":"AR Sanchez-Paulete","year":"2016","unstructured":"Sanchez-Paulete, A. R. et al. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. Eur. J. Immunol. 46, 513\u2013522 (2016).","journal-title":"Eur. J. Immunol."},{"key":"39196_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.canlet.2020.11.041","volume":"499","author":"ST Muth","year":"2021","unstructured":"Muth, S. T. et al. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma. Cancer Lett. 499, 99\u2013108 (2021).","journal-title":"Cancer Lett."},{"key":"39196_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27613-w","volume":"12","author":"I Otano","year":"2021","unstructured":"Otano, I. et al. CD137 (4-1BB) costimulation of CD8(+) T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. Nat. Commun. 12, 7296 (2021).","journal-title":"Nat. Commun."},{"key":"39196_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1084\/jem.186.1.47","volume":"186","author":"WW Shuford","year":"1997","unstructured":"Shuford, W. W. et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T-cell responses. J. Exp. Med. 186, 47\u201355 (1997).","journal-title":"J. Exp. Med."},{"key":"39196_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1182\/blood-2006-11-056168","volume":"110","author":"M Wolfl","year":"2007","unstructured":"Wolfl, M. et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110, 201\u2013210 (2007).","journal-title":"Blood"},{"key":"39196_CR16","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00262-012-1237-1","volume":"61","author":"TS Fisher","year":"2012","unstructured":"Fisher, T. S. et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol. Immunother. 61, 1721\u20131733 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"39196_CR17","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3390\/ijms20081822","volume":"20","author":"D-T Chu","year":"2019","unstructured":"Chu, D.-T. et al. An update on anti-CD137 antibodies in immunotherapies for cancer. Int. J. Mol. Sci. 20, 1822 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"39196_CR18","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","volume":"23","author":"NH Segal","year":"2017","unstructured":"Segal, N. H. et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin. Cancer Res. 23, 1929\u201336. (2017).","journal-title":"Clin. Cancer Res."},{"key":"39196_CR19","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.5858\/134.4.e14","volume":"134","author":"MK Washington","year":"2010","unstructured":"Washington, M. K. et al. Protocol for the examination of specimens from patients with carcinoma of the intrahepatic bile ducts. Arch. Pathol. Lab. Med. 134, e14\u2013e18 (2010).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"39196_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/SLA.0b013e3181fd271c","volume":"253","author":"E Lutz","year":"2011","unstructured":"Lutz, E. et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann. Surg. 253, 328\u2013335 (2011).","journal-title":"Ann. Surg."},{"key":"39196_CR21","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","volume":"27","author":"KT Byrne","year":"2021","unstructured":"Byrne, K. T. et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin. Cancer Res. 27, 4574\u201386. (2021).","journal-title":"Clin. Cancer Res."},{"key":"39196_CR22","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy, T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395\u2013406. (2018).","journal-title":"N. Engl. J. Med."},{"key":"39196_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos, J. P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389, 1011\u20131024 (2017).","journal-title":"Lancet"},{"key":"39196_CR24","doi-asserted-by":"publisher","first-page":"S226","DOI":"10.1016\/j.annonc.2021.06.009","volume":"32","author":"M Tempero","year":"2021","unstructured":"Tempero, M. et al. LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): updated 5-year overall survival. Ann. Oncol. 32, S226 (2021).","journal-title":"Ann. Oncol."},{"key":"39196_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo, D., Demartines, N. & Clavien, P. A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 240, 205\u2013213 (2004).","journal-title":"Ann. Surg."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-39196-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-39196-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-39196-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T08:03:23Z","timestamp":1687248203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-39196-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["39196"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-39196-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.Z. receives grant support from Bristol-Meyer Squibb, Merck, Astrazeneca, iTeos, Amgen, NovaRock, Inxmed, and Halozyme. L.Z. is a paid consultant\/Advisory Board Member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia\/Xilio, QED, Natera, Novagenesis, Snow Lake Capitals, BioArdis, Amberstone Biosciences, Tempus, Pfizer, Tavotek Lab, ClinicalTrial Options, LLC, and Mingruizhiyao. L.Z. holds shares at Alphamab, Amberstone, and Mingruizhiyao. E.J. reports other support from Abmeta and Adventris, personal fees from Achilles, Dragonfly, Mestag, The Medical Home Group, and Surgtx, other support from Parker Institute, grants and other support from the Lustgarten Foundation, Genentech, BMS, and Break Through Cancer outside the submitted work. D.T.L. serves on advisory boards for Merck, Bristol Myers Squibb, Nouscom, G1 Therapeutics, Janssen, and Merus and has received research funding from Merck, Bristol Myers Squibb, Curegenix, Nouscom, and Abbvie. She has received speaking honoraria from Merck and is an inventor of licensed intellectual property related to technology for mismatch repair deficiency for diagnosis and therapy (WO2016077553A1) from Johns Hopkins University. The terms of these arrangements are being managed by Johns Hopkins. R.A. receives grant support from Bristol-Meyer Squibb, RAPT Theraputics. R.A. is a paid consultant for Bristol-Meyer Squibb, Merck, Astrazeneca. The remaining authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3650"}}